Summary
Eli Lilly and Company has announced its acquisition of Centessa Pharmaceuticals, a company focused on developing treatments for rare diseases and neurodegenerative disorders. The deal, valued at $6.3 billion, will give Lilly access to Centessa’s diverse pipeline of potential therapies, including a promising treatment for sleep disorder narcolepsy. The acquisition is expected to close in the third quarter of 2021.
Access impact
The acquisition of Centessa by Lilly has significant implications for pricing, reimbursement, and health technology assessment (HTA) decisions. The addition of Centessa’s pipeline to Lilly’s already robust portfolio strengthens the company’s position in the competitive neuroscience market, potentially leading to higher prices for these treatments. Additionally, reimbursement and HTA evaluations will need to consider the potential benefits and risks of these rare disease and neurodegenerative disorder therapies.
Top-3 domain lens
Clinical Effectiveness
Lilly’s acquisition of Centessa’s pipeline brings a range of potential treatments for rare diseases and neurodegenerative disorders. These therapies have shown promising results in early clinical trials, but further studies will be needed to establish their clinical effectiveness and safety.
Cost-Effectiveness
The addition of Centessa’s pipeline to Lilly’s portfolio may lead to higher prices for these rare disease and neurodegenerative disorder treatments. As such, payers and HTA agencies will need to carefully assess the cost-effectiveness of these therapies in comparison to existing treatments.
Safety and Tolerability
The potential side effects and tolerability of Centessa’s therapies will need to be closely examined by payers and HTA agencies. While early trials have shown promising results, further research will be needed to fully understand the safety profile of these treatments.
Hashtags
#MarketAccessRiskAssessment #Pricing #Reimbursement #MarketAccess #MARArating #Company #Drug
CTA
Explore 350+ independent assessments: https://mararating.com/mara-ratings-list
Source
source: https://www.biopharmadive.com/news/lilly-centessa-6B-dollar-buyout-sleep-narcolepsy-drug/816226/